Journey Strategic Wealth LLC Acquires 1,275 Shares of Stryker Corporation $SYK

Journey Strategic Wealth LLC increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 206.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,894 shares of the medical technology company’s stock after acquiring an additional 1,275 shares during the quarter. Journey Strategic Wealth LLC’s holdings in Stryker were worth $749,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of SYK. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Stryker in the 2nd quarter worth about $26,000. Sachetta LLC boosted its stake in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 27 shares during the last quarter. Ridgewood Investments LLC grew its position in shares of Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares during the period. Ransom Advisory Ltd purchased a new stake in shares of Stryker during the 1st quarter worth approximately $37,000. Finally, MTM Investment Management LLC bought a new stake in shares of Stryker in the 2nd quarter worth approximately $38,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Evercore ISI decreased their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. BTIG Research reissued a “buy” rating and issued a $410.00 price objective on shares of Stryker in a report on Friday, November 14th. Barclays increased their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Finally, UBS Group set a $408.00 price target on shares of Stryker in a research note on Monday, October 13th. Thirteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Trading Up 2.2%

Shares of SYK stock opened at $368.35 on Friday. The company has a market capitalization of $140.87 billion, a PE ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The business’s fifty day moving average is $369.38 and its 200 day moving average is $380.68. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same period in the previous year, the business earned $2.87 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Activity at Stryker

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 522,618 shares of company stock valued at $185,577,237 in the last ninety days. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.